COMPANY
Accutar Biotechnology
Timeline
- Trial start Phase 1: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies source ↗
- Trial start Phase 1: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer source ↗
- Trial start Phase 1: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer source ↗
- Trial start Phase 1: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer source ↗
- Trial start Phase 1: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer source ↗
- Trial start Phase 1: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer source ↗
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05780034 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Phase 1 | Recruiting | Jun 20, 2023 | Mar 31, 2026 (estimated) |
| NCT05654532 | Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer | Phase 1 | Active, not recruiting | Dec 29, 2022 | Mar 31, 2026 (estimated) |
| NCT05080842 | A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | Phase 1 | Terminated | Nov 12, 2021 | Apr 4, 2024 (actual) |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Mar 16, 2022 | Mar 5, 2024 (actual) |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Feb 22, 2023 | Oct 8, 2023 (actual) |
| NCT05489679 | A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | Phase 1 | Terminated | Oct 1, 2022 | Sep 28, 2023 (actual) |